The story of Sildenafil presents a complex picture for investors. While the initial launch generated substantial returns, the lapse of its patent opened the floodgates to generic alternatives, dramatically eroding sales. This creates a particular risk for firms banking on similar blockbuster medications, suggesting that a unquestioning stake in the

The legacy of Viagra, and its parent company copyright, presents a complex case study for investors. Originally a blockbuster drug, producing billions in revenue , its exclusivity period created a flood of knock-off medications, significantly impacting its dominance. While specific businesses may try to capitalize on related treatments , the existi